Grenoble, France, and Epalinges, Switzerland, December 12th, 2017  – PX’Therapeutics, a CDMO specializing in the development of recombinant proteins for human and animal health, is proud to announce the end of the rgp41 manufacturing campaign and batch certification for clinical application. This drug substance will be used by Mymetics to develop a new vaccine formulation, within the framework of the MACIVIVA project, sustained by the European Union’s Horizon 2020 research and innovation program and the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners.

Rgp41 protein is one of the HIV-1 gp41 derived antigens constituting Mymetics’ HIV-1 vaccine that is anchored to the membrane surface of the virosome particle, which acts as vaccine delivery vehicle for soliciting the immune system for inducing the production of protective serum and mucosal antibodies.

PX’Therapeutics and Mymetics joined forces several years ago to work on rgp41 protein design and development of the production and purification processes of the molecule. PX teams managed to develop an efficient, scalable and GMP-compliant process. A clinical batch was produced from a scale fermentation volume of 120 L to deliver a sufficient quantity for formulation studies and clinical trials.

Claire Untereiner, Chief Operating Officer of PX’Therapeutics, commented as follows: “We are so happy to see the progress made with this molecule and to be part of this fantastic project. MACIVIVA’s objective, the development of cold-chain independent and virosome-based vaccines, responds to a real medical need, particularly in emerging countries, and is in line with PX’Therapeutics’ mission, to support and accelerate the development of innovative medicines”.

Sylvain Fleury, Chief Scientific Officer of Mymetics SA commented: “we are pleased that PX’Therapeutics could address many technical challenges related to the GMP development of the recombinant rgp41 protein and achieve a production yield superior to our expectations. With this rgp41, Mymetics will further pursue the development of its HIV-1 candidate vaccine, which could be administered through various immunization routes, as a standalone product or combined with viral vectors in a prime-boost approach”.

Press release.

Contacts

PX’Therapeutics
Claire Untereiner
Chief Operating Officer
7 parvis Louis Néel – CS20050 BHT52A
38040 Grenoble Cedex – FRANCE
Phone: +33 (0)4.38.02.36.50
Claire.untereiner@px-therapeutics.com

Mymetics
Ronald Kempers
CEO
Route de la Corniche 4
1066 Epalinges – Switzerland
Phone : +41 21 653 4535
info@mymetics.com

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *